mipragoside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

mipragoside: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	76966493
CHEMBL ID	3989544
MeSH ID	M0211891

Synonyms (15)

Synonym
unii-ior159kl0h
mipragosido
ior159kl0h ,
n-(ii(sup 3)-n-acetylneuraminosylgangliotetraosyl)ceramide, isopropyl ester
octadecanamide, n-((1s,2r,3e)-1-(((o-(n-acetyl-1-(1-methylethyl)-alpha-neuraminosyl)-(2-3)-o-(o-beta-d-galactopyranosyl-(1-3)-2-(acetylamino)-2-deoxy-beta-d-galactopyranosyl-(1-4))-o-beta-d-galactopyranosyl-(1-4)-beta-d-glucopyranosyl)oxy)methyl)-2-hydrox
octadecanamide, n-(1-(((o-(n-acetyl-1-(1-methylethyl)-alpha-neuraminosyl)-(2-3)-o-(o-beta-d-galactopyranosyl-(1-3)-2-(acetylamino)-2-deoxy-beta-d-galactopyranosyl-(1-4))-o-beta-d-galactopyranosyl-(1-4)-beta-d-glucopyranosyl)oxy)methyl)-2-hydroxy-3-heptade
mipragoside
131129-98-1
mipragosido [inn-spanish]
mipragosidum [inn-latin]
mipragosidum
mipragoside [inn]
agf 44
CHEMBL3989544
Q27280827

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	4 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (20.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	4 (80.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
formaldehyde paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy	1.98	1	0	aldehyde; one-carbon compound	allergen; carcinogenic agent; disinfectant; EC 3.5.1.4 (amidase) inhibitor; environmental contaminant; Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
g(m1) ganglioside G(M1) Ganglioside: A specific monosialoganglioside that accumulates abnormally within the nervous system due to a deficiency of GM1-b-galactosidase, resulting in GM1 gangliosidosis.. ganglioside GM1 : A sialotetraosylceramide consisting of a branched pentasaccharide made up from one sialyl residue, two galactose residues, one N-acetylgalactosamine residue and a glucose residue at the reducing end attached to N-stearoylsphingosine via a beta-linkage.	4.28	4	1	alpha-N-acetylneuraminosyl-(2->3)-[beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl-(1->4)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acylsphingosine; sialotetraosylceramide

Condition	Relationship Strength	Studies	Trials
Allergic Conjunctivitis [description not available]	3.77	2	1
Leukoma [description not available]	1.98	1	0
Active Hyperemia [description not available]	1.98	1	0
Conjunctivitis, Allergic Conjunctivitis due to hypersensitivity to various allergens.	3.77	2	1
Corneal Opacity Disorder occurring in the central or peripheral area of the cornea. The usual degree of transparency becomes relatively opaque.	1.98	1	0
Hyperemia The presence of an increased amount of blood in a body part or an organ leading to congestion or engorgement of blood vessels. Hyperemia can be due to increase of blood flow into the area (active or arterial), or due to obstruction of outflow of blood from the area (passive or venous).	1.98	1	0
Alloxan Diabetes [description not available]	1.98	1	0
Ache [description not available]	1.98	1	0
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	1.98	1	0
Innate Inflammatory Response [description not available]	1.98	1	0
Primary Peritonitis [description not available]	1.98	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	1.98	1	0
Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.	1.98	1	0

chemdatabank.com